+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 7 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating treatments for patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated breast cancer that is locally advanced or metastatic. This phase III, global, randomized, open-label study compares the effectiveness and safety of inavolisib combined with fulvestrant versus alpelisib combined with fulvestrant. Participants have experienced disease progression during or after therapy with cyclin dependent kinase 46 inhibitors combined with endocrine therapy. Participants receive study drugs in repeated 28-day cycles. Inavolisib is taken orally once daily at 9 mg on days 1 to 28 of each cycle, while fulvestrant is administered at 500 mg on days 1 and 15 of the first cycle and day 1 of subsequent cycles. The comparator group receives alpelisib at 300 mg orally once daily plus fulvestrant on the same schedule. A substudy evaluates the effect of inavolisib plus fulvestrant on the metabolism of certain enzyme substrates by administering midazolam, omeprazole, and bupropion on specified days within the first cycle. Participants undergo regular assessments including tumor evaluations per RECIST criteria, blood tests, and monitoring of drug levels. The primary outcome measures progression-free survival assessed by independent review up to approximately 64 months. Secondary outcomes include overall survival, response rates, quality of life, and safety events monitored up to about 85 months. The study includes frequent visits during treatment cycles and follow-ups to evaluate side effects and long-term outcomes.

Age: 18Years +All GendersPhase 3
210 locations
P

Actively Recruiting

Researchers are evaluating the safety and performance of the RTD Wound Dressing compared to the current standard care device used by the NHS for treating non-infected neuropathic, ischaemic, and neuro-ischaemic diabetic foot ulcers. This clinical evaluation is conducted in an open-label, randomized design within NHS Lanarkshires diabetic foot clinics. The primary goals are to assess complete wound healing and reduction in wound area after 12 weeks. Participants will be randomly assigned to either receive the RTD Wound Dressing, which is already CE marked and used for its intended purpose, or the NHS standard dressing normally used in podiatry clinics. Both groups will continue their regular NHS podiatry appointments. The study compares outcomes between these two groups over the 12-week period. During the study, participants will attend routine clinic visits where wound healing progress, wound area reduction, infection rates, and dressing changes will be monitored. Researchers will use medical photography and other evaluations to track healing and safety. Participants must be able to follow instructions and provide informed consent. The total follow-up period is 12 weeks with assessments focused on wound healing and related outcomes.

Age: 18Years +All GendersPhase Not Applicable
2 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are studying the effectiveness of the IGEL laryngeal mask airway device in patients who have had radiation therapy to the neck. These patients face a higher risk of difficult mask ventilation and tracheal intubation during general anesthesia compared to most patients. The study aims to understand how well the IGEL device works as a rescue tool for maintaining oxygenation in this high-risk group, where failure to maintain oxygen can cause severe brain injury or death. The study involves inserting the IGEL device in anesthetized patients who have previously received radiotherapy to the neck. This device is being evaluated as a method to ensure adequate ventilation during surgery. The procedure is planned by physicians and is part of elective surgeries requiring general anesthesia. The study focuses on how successfully the device can be placed and used to ventilate the patient within a 10-minute timeframe. Participants will undergo the insertion of the IGEL device during their scheduled surgery. Researchers will assess the success of device placement and ventilation during this time. Data collected will focus on the effectiveness of airway control with this device in patients with previous neck radiation. The study does not involve blinding or comparison groups and will continue until September 2027. Participants are monitored closely to ensure safety during the procedure.

Age: 18Years +All GendersPhase Not Applicable
1 location
O

Actively Recruiting

Researchers are conducting an observational study to understand the psychiatric and general medical conditions of adults admitted to NHS General Adult Psychiatry GAP inpatient wards. This study aims to provide detailed information on the health challenges faced by these patients, who often have complex conditions that may exclude them from typical clinical trials. The findings will help compare real-life GAP patients with those in clinical trials, potentially explaining differences in treatment outcomes. Participants include 100 adults aged 18 to 65 who are admitted to GAP wards and have mental health disorders that their general practitioners cannot treat. The study involves completing questionnaires, severity rating scales, and a review of medical case notes. Participants will be grouped based on their psychiatric diagnosis, such as schizophrenia, bipolar disorder, depression, or personality disorders. During the study, participants will spend about an hour completing questionnaires and discussing their health with a clinician. Researchers will collect data on psychiatric diagnoses, severity of symptoms psychosis, depression, mania, anxiety, substance use, physical illnesses, and treatment resistance. This data collection occurs at enrollment, with no treatment given, and participants can withdraw at any time. The study results will provide a baseline for better understanding the health of GAP patients.

Age: 18Years - 65YearsAll Genders
1 location
C

Actively Recruiting

Researchers are conducting a phase III, randomized, open-label, international trial to compare ruxolitinib with the best available therapy, which includes either hydroxycarbamide or interferon alpha, as first-line treatment for patients with high-risk polycythemia vera. This trial aims to assess the effectiveness and safety of these treatments in managing the disease and preventing major complications such as thrombosis and transformation to other blood disorders. Participants will be randomly assigned to receive either ruxolitinib at a dose of 10 mg twice daily or best available therapy consisting of hydroxycarbamide or any formulation of interferon alpha chosen by the investigator before randomization. The study prohibits crossover between treatment arms during the trial period. Treatment and monitoring will continue for approximately 3 years, with assessments of blood markers, symptom burden, quality of life, and adverse events. During the trial, participants will have regular visits for monitoring their health, including blood tests for JAK2 V617F allele burden, quality of life questionnaires at several time points, and evaluation of clinical events such as thrombosis, haemorrhage, and disease progression. The primary outcome measured is event-free survival, defined by the time until major complications or death within the trial duration. Safety, symptom changes, and other secondary outcomes will be assessed continuously throughout the study, which is planned to complete by 2030.

Age: 18Years +All GendersPhase 3
55 locations
S

Actively Recruiting

This research aims to understand how adults recover after leaving the intensive care unit ICU by using a wrist-worn activity monitor. The study focuses on people discharged from the ICU in three hospitals in Edinburgh, examining whether movement data can provide useful insights into their health and recovery. It also looks at how changes in activity relate to symptoms like pain, anxiety, daily functioning, sleep, and cognition. There is no comparison group in this observational study. Participants wear a wrist-worn accelerometer on their dominant wrist continuously for two months after hospital discharge. Alongside this, they complete regular telephone assessments that measure health-related quality of life, physical ability, sleep quality, and cognitive function. These questionnaires occur at baseline, 2 weeks, 1 month, and 2 months after discharge. The study collects movement and patient-reported data to identify early digital signs of recovery problems or unmet rehabilitation needs. During the study, participants are monitored remotely through their wearable device and telephone questionnaires. Researchers track the feasibility of collecting wearable data and the completion rates of health surveys. They also observe outcomes such as hospital readmissions and mortality within two months after discharge. The total participant involvement lasts for two months post-hospital discharge, with repeated assessments to understand recovery patterns and support needs.

Age: 18Years +All Genders
3 locations
E

Actively Recruiting

Researchers are evaluating a new sixth-generation high-sensitivity cardiac troponin T test to diagnose heart attacks more quickly among patients with suspected acute coronary syndrome. This diagnostic study aims to determine if using this advanced test reduces the time patients spend in Emergency Departments while maintaining patient safety. The study compares data from one year before and one year after introducing the new test across a health board, using routinely collected hospital data and blood samples. The study involves two groups patients evaluated with the current fifth-generation troponin test before the new tests implementation, and those evaluated with the sixth-generation test afterward. The sixth-generation Elecsys Troponin T hs Gen 6 assay is designed to be more precise and less affected by interference than the previous version. Researchers will measure troponin levels from surplus blood samples collected during two six-month periods before and after the new tests introduction to directly compare the tests. Participants will not need to take any extra actions as the study uses data and samples collected during usual care. Researchers will examine Emergency Department length of stay as the primary outcome, along with hospital admission, cardiovascular events, and mortality up to one year. The study will also monitor serial troponin measurements and other clinical outcomes to assess the new tests impact on patient care and safety over time.

Age: 18Years +All GendersPhase Not Applicable
3 locations